Wyeth

American Cyanamid Company

Wyeth Holdings Corporation

Nan Zhang

Allan Wissner

Hwei-Ru Tsou

Dan Maarten Berger

Diane H Boschelli

Biqi Wu

Semiramis Ayral-Kaloustian

Dennis William Powell

Fei Ye

Frenel Fils DeMorin

Middleton B Floyd, Jr

Michael Peter Trova

Philip R Hamann

Philip Frost

Minu D Dutia

Ayako Yamashita

Yanong Daniel Wang

Elsebe Geraldine Overbeek-Klumpers

Frank Boschelli

Haris Durutlic

Thai Nguyen

Ana Carolina Barrios Sosa

Mark E Salvati

Yanzhong Wu

Douglas Bruce Kitchen

Steven R Schow

Bernard D Johnson

Philip Ross Hamann

Robert E Babine

Wei Tong

This invention provides compounds of formula I having the structure wherein G, G, R, R, Z, n, and X are defined in the specification or a pharmaceutically acceptable salt thereof which are useful as antineoplastic agents and in the treatment of polycystic kidney disease.

Substituted 3-cyanoquinolines

This invention relates to methods for treating or inhibiting cancers in a mammal in need thereof, which comprises administering an effective amount of a 6-Aryl-7-halo-imidazo[1,2 -a]pyrimidine compound of the formula: or pharmaceutically acceptable salts thereof.

6-aryl-7-halo-imidazo[1,2-a]pyrimidines as anticancer agents

This invention relates to certain 5-arylpyrimidine compounds or a pharmaceutically acceptable salt thereof, and compositions containing said compounds or a pharmaceutically acceptable salt thereof, wherein said compounds are anti-cancer agents useful for the treatment of cancer in mammals. This invention further relates to a method of treating or inhibiting the growth of cancerous tumor cells and associated diseases in a mammal and further provides a method for the treatment or prevention of cancerous tumors that express multiple drug resistance (MDR) or are resistant because of MDR, in a mammal in need thereof which method comprises administering to said mammal an effective amount of said compounds or a pharmaceutically acceptable salt thereof. More specifically, the present invention relates to a method of treating or inhibiting the growth of cancerous tumor cells and associated diseases in a mammal in need thereof by promotion of microtubule polymerization which comprises administering to said mammal an effective amount of said compounds and pharmaceutically acceptable salts thereof.

5-arylpyrimidines as anticancer agents

This invention relates to certain 6-[(substituted)phenyl]triazolopyrimidine compounds or pharmaceutically acceptable salts thereof, and compositions containing said compounds or pharmaceutically acceptable salts thereof, wherein said compounds are anti-cancer agents useful for the treatment of cancer in mammals. This invention further relates to a method of treating or inhibiting the growth of cancerous tumor cells and associated diseases in a mammal and further provides a method for the treatment or prevention of cancerous tumors that express multiple drug resistance (MDR) or are resistant because of MDR, in a mammal in need thereof which method comprises administering to said mammal an effective amount of said compounds or pharmaceutically acceptable salts thereof. The present invention relates to a method of treating or inhibiting the growth of cancerous tumor cells and associated diseases in a mammal in need thereof by promotion of microtubule polymerization which comprises administering to said mammal an effective amount of said compounds and pharmaceutically acceptable salts thereof.

6-[(substituted)phenyl]triazolopyrimidines as anticancer agents

This invention relates to certain 6-aryl-7-halo-imidazo[1,2-a]pyrimidines or pharmaceutically acceptable salts thereof, and compositions containing said compounds or pharmaceutically acceptable salts thereof, wherein said compounds are anti-cancer agents useful for the treatment of cancer in mammals by promotion of microtubule polymerization. This invention further relates to a method of treating or inhibiting the growth of cancerous tumor cells and associated diseases in a mammal and further provides a method for the treatment or prevention of cancerous tumors that express multiple drug resistance (MDR) or are resistant because of MDR, in a mammal in need thereof which method comprises administering to said mammal an effective amount of said compounds or pharmaceutically acceptable salts thereof.

This invention provides compounds of Formula (1)&#x2013;(1), II wherein:

Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors

This invention provides compounds of formula 1, having the structure which are useful as inhibitors of protein tyrosine kinase and are antiproliferative agents.

Tricyclic protein kinase inhibitors

This invention provides compounds of Formula (1a)-(1f)wherein:

3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors

This invention provides compounds of formula I having the structure

This invention provides compounds of formula 1 having the structure

Substituted quinazoline derivatives

This invention provides a compound having the formula: ##STR1## wherein: (A) n=2-4;

Growing community of inventors

Bayside, NY, United States of America

Nan Zhang